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A hybrid linear ion-trap Fourier-transform ion cyclotron resonance mass spectrometer was
used for top-down characterization of the abundant human salivary cystatins, including S, S1,
S2, SA, SN, C, and D, using collisionally activated dissociation (CAD) after chromatographic
purification of the native, disulfide intact proteins. Post-translational modifications and
protein sequence polymorphisms arising from single nucleotide polymorphisms (SNPs) were
assigned from precursor and product ion masses at a tolerance of 10 ppm, allowing confident
identification of individual intact mass tags. Cystatins S, S1, S2, SA, and SN were cleaved of a
N-terminal 20 amino acid signal peptide and cystatin C a 26-residue peptide, to yield a
generally conserved N-terminus. In contrast, cystatin D isoforms with 24 and 28 amino acid
residue N-terminal truncations were found such that their N-termini were not conserved.
Cystatin S1 was phosphorylated at Ser3, while S2 was phosphorylated at Ser1 and Ser3, in
agreement with previous work. Both cystatin D isoforms carried the polymorphism C46R
(SNP: rs1799841). The 14,328 Da isoform of cystatin SN previously assigned with polymor-
phism P31L due to a SNP (rs2070856) was found only in whole saliva. Parotid secretions
contained no detectable cystatins while whole saliva largely mirrored the contents of
submandibular/sublingual (SMSL) secretions. With fully characterized cystatin intact
mass tags it will now be possible to examine the correlation between the abundance of
these molecules and human health and disease. (J Am Soc Mass Spectrom 2010, 21,
908–917) © 2010 American Society for Mass SpectrometryHigh-resolution mass spectrometry (MS) of in-tact proteins led to the inception of the “top-down” approach 10 y ago [1]. Intact proteins
are introduced into the gas phase by electrospray ion-
ization (ESI) for high-resolution mass measurements of
intact protein precursor ions before direct dissociation
for product ion mass measurements. The top-down
precursor and product ion datasets are then reconciled
with the primary structure of the protein, including all
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doi:10.1016/j.jasms.2010.01.025modifications that affect mass. The advent of top-down
MS was proceeded by cornerstone developments in the
field of mass spectrometry, including the application of
high-resolution Fourier-transform ion cyclotron reso-
nance mass spectrometry (FT-ICR-MS) to larger biomol-
ecules [2], the ability to ionize intact proteins and
dissociate them in the mass spectrometer [3], and the
ability to identify proteins from such experiments using
sequence tags [4], as well as the availability of genomic
sequence data. However, limited availability of high-
resolution instrumentation and relatively low through-
put issues compared with bottom-up shotgun ap-
proaches have limited the contribution that top-down
MS has made to the field of proteomics. The biomarker
field has embraced intact protein screening for several
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hampered by the use of low-resolution instrumentation
and the difficulties of subsequent unequivocal identifi-
cation of promising candidates. High-resolution tan-
dem mass spectrometry offers the ability to overcome
these issues since intact mass tags from candidate
biomarker can be directly analyzed by the top-down
strategy. We show that simple top-down experiments
can reliably link a protein identification to a low-
resolution (or high-resolution) intact mass tag.
Saliva is produced in and secreted from three major
pairs of salivary glands (submandibular, sublingual,
and parotid), and is composed of water and other
compounds, including electrolytes, mucus, antibacterial
molecules, and a variety of proteins [5]. Saliva has a
variety of protective functions, including lubrication,
antimicrobial activity, mucosal integrity, lavage/cleansing,
buffering, and remineralization, as well as other oral
functions such as digestion, taste, and speech [6]. There
is considerable interest in saliva because of its easy
accessibility compared with nearly all other body fluids
and the possibility that it might yield useful biomarkers
or biosignatures of health and disease. The cystatins are
a family of cysteine protease inhibitors found in human
saliva with highest concentrations in submandibular
secretions and little present in parotid [7, 8]. Included
within this family are cystatins S, S1, S2, SA, SN, C, and
D. These proteins typically have between 120 and 121
amino acids after signal sequence cleavage, molecular
weights in the 13 to 14 kDa range, and two conserved
disulfide bonds [9, 10]. The cystatins are known to
inhibit cysteine proteases of both host and microbial
origin, thereby preventing harmful proteolysis of the
tissues of the oral cavity that could otherwise facilitate
microbial infection [11]. A growing body of literature
reports cystatins as putative biomarkers of human
disease, and expression levels of various members of
the family found not only in saliva but also in blood,
cerebrospinal fluid, and urine have been correlated
with a range of conditions. Cystatin C is most widely
discussed, with links to many different medical condi-
tions including cancer [12], diabetes and kidney disease
[13], heart disease [14], neurotrauma [15], and neurode-
generation [16]. Cystatin SN has shown some promise
as a urinary biomarker for colorectal cancer [17], and
cystatin SA as a saliva marker for oral cancer [18].
Interestingly, studies where the intact proteins were
measured have suggested that it was an abnormally
truncated form of the protein that was the marker; loss
of an extra three amino acids from the N-terminus of
cystatin SA-1 (SN) [18] or loss of an extra eight amino
acids from the N-terminus of cystatin S [19].
Bearing in mind these observations, we report a
high-resolution mass spectrometry study of the native
forms of human salivary cystatins. Collisionally acti-
vated dissociation (CAD) was used to identify and fully
describe selected intact mass tags corresponding to the
major detectable forms of cystatins isolated from hu-
man saliva. Interpretation of the data required consid-eration of post-translational modifications, including
N-terminal signal peptide removal, disulfide formation,
and phosphorylation, as well as protein sequence poly-
morphisms arising from single nucleotide polymor-
phisms (SNPs). The ability to directly identify potential
biomarkers should empower intact protein biomarker
screening.
Experimental
Chemicals
All chemicals were purchased from Fisher Scientific,
Waltham, MA, USA.
Sample Collection
Adult saliva donors of various ethnic and racial back-
grounds, ranging in age from 22 to 30 y, were recruited
from the general population, and samples were col-
lected at the UCLA Medical Center with full donor
consent, using procedures in accord with the Medical
Institution Review Board and the Office of Protection
for Research Subjects, as previously described [20].
Whole saliva (WS) was collected in an unstimulated
fashion, while parotid (P), submandibular (SM), and
sublingual (SL) secretions were collected after applica-
tion of an aqueous citric acid solution (2%), as previ-
ously described [20]. Collected samples were centri-
fuged (10,000  g, 15 min, 4 °C), the supernatant was
then treated with protease/phosphatase inhibitors
(aprotinin, 1 L/mL saliva, 10 mg/mL; sodium or-
thovanadate, 3 L/mL saliva, 400 mM; phenylmethyl
sulfonyl fluoride, 10 L/mL saliva, 10 mg/mL) added
promptly while the sample was on ice. Samples were
then aliquoted and stored at80°C before MS analyses.
Reversed-Phase Chromatography with Online
Electrospray-Ionization Mass Spectrometry and
Fraction Collection (LC-MS)
Pooled samples (1 mL) were dried by centrifugal evap-
oration, re-dissolved in 400 mL 6 M guanidine-HCl and
centrifuged (10,000  g, 5 min, room temperature).
Aliquots (4  100 L) of the resulting supernatants
were then injected onto a reversed-phase HPLC column
(PLRP/S 5 m, 300 Å, 2.1 mm  150 mm; Varian Inc.,
Palo Alto, CA, USA) equilibrated in water/acetonitrile/
TFA (95/5/0.1, vol/ vol) and eluted (100 L/min,
40 °C) with an increasing concentration of acetonitrile
(min/% acetonitrile; 0/5, 5/5, 10/20, 70/50, 90/90). The
eluent was passed through a UV detector (280 nm)
before a flow splitter with fused silica capillaries to
transfer liquid to the low-resolution ESI source (50 cm)
and the fraction collector (25 cm). Fractions collected
into microcentrifuge tubes at 1 min intervals were
stored at 80 °C before off-line high-resolution nano-
spray analysis.
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Spectrometry
LC-MS experiments were performed using a triple
quadrupole instrument (API III, Applied Biosystems,
Foster City, CA, USA) tuned and calibrated using a PEG
mixture as described previously [21]. Spectra were
recorded by scanning from m/z 600–2300 with the
orifice voltage ramped with mass (60–120) using a 0.3
Da step size and a scan speed of 6 s. Data were
processed using MacSpec 3.3, or BioMultiview 1.3.1
software (Applied Biosystems).
High-Resolution Electrospray Ionization Mass
Spectrometry
Top-down mass spectrometry was performed on a
hybrid linear ion-trap 7 T FT-ICR mass spectrometer
(LTQ-FT Ultra; Thermo Fisher Corp., San Jose, USA)
fitted with an off-line nanospray source. HPLC fractions
were individually loaded into 2 m i.d. externally
coated nanospray emitters (Proxeon, Cambridge, MA,
USA) and desorbed using a spray voltage of 1.8 kV
(versus the inlet of the mass spectrometer). These con-
ditions produced a flow rate of 20–50 nL/min. Ion
transmission into the linear trap and further to the ICR
cell was automatically optimized for maximum ion
signal. The ion count targets for the full scan and MS2
experiments were 2  106. The m/z resolving power of
the instrument was set at 100,000 (defined by m/m
50% at m/z 400). Individual charge states of the multi-
ply protonated molecular ions were selected for isola-
tion and collisional activation in the linear ion trap
followed by the detection of the resulting fragments in
the ICR cell. Helium was used as collision gas in the
LTQ mass spectrometer, which was operated in the
standard mass range of m/z 300–2000. Precursor ions
were isolated with widths of m/z 4–8 to maximize
homogeneity of the ion while maintaining maximal
signal strength. Precursors were activated using colli-
sion energy settings between 12 and 15 at the default
activation q-value of 0.25 [22].
Data Analysis with ProSight PC
All top-down FT-ICR spectra were obtained by averag-
ing between 50 and 200 transient signals. Precursor
masses were calculated using Xtract version 3.0.1.1
(Thermo Scientific, Bremen, Germany) with S/N
threshold of 2, minimum intensity of 2, minimum fit of
30, and a remainder threshold of 3. Product ion spectra
were processed using ProSight PC version 2 (Thermo
Scientific) to produce monoisotopic mass lists (S/N 2;
minimum RL value 0.9). Where identity was not
known, sequence tags were compiled for sequence tag
searching to generate candidates for further manual
fitting. The absolute mass search mode was used for
refinement of primary structure to maximize agreement
of precursor and product ions matched. Mass tolerancewas set at 10 ppm and the deltamass feature was
deactivated. All protein sequence databases were taken
from SwissProt entries. Data files (raw) and peaklists
(.puf) extracted from them are contained in the supple-
mentary material which can be found in the electronic
version of this article.
Figure 1. Reversed-phase chromatography of human salivary
proteins. Whole saliva, as well as parotid and submandibular/
sublingual ductal secretions, were dried and dissolved in 6 M
guanidine before separation by HPLC and online ESI mass spec-
trometry with fraction collection (LC-MS; see the Methods
section). Typical total ion chromatograms are shown highlighting
the region where the cystatin family elutes. Intact cystatins were
found in only whole saliva and SMSL secretions.
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Chromatographic Separation of Proteins from
Whole (WS), Submandibular/Sublingual (SMSL),
and Parotid (PR) Saliva
Pooled human saliva samples were dried and dissolved in
6 M guanidine before immediate reversed-phase chroma-
tography with online ESI mass spectrometry and concom-
itant fraction collection LC-MS [23]. The results of the
low-resolution mass analysis were used to select fractions
and protein-specific ions for further top-down high-
resolution MS analysis. The three saliva samples collected
from the 3-primary glandular sources produced moder-
ately complex, partially super-imposable total ion chro-
matograms (Figure 1). While the profiles were similar, it
was readily apparent that the cystatin family of proteins,
that eluted in the range 45–60 min, were poorly repre-
sented in PR secretions compared to SMSL and WS, in
agreement with previous studies [24, 25]. Top-down anal-
yses were then performed on stored fractions from the
original LC-MS experiment to characterize this family of
proteins as thoroughly as possible, especially with respect
to post-translational modifications and variants due to
single-nucleotide polymorphisms (SNPs) that were previ-
ously detected in a preliminary high-resolution analysis of
salivary proteins [26]. In Table 1, the average mass deter-
mined in the original low-resolution LC-MS is included
to allow facile comparison with other mass spectral data
Table 1. Human salivary cystatins
Cystatin Swiss-Prot
No.
amino
acids Modification
M
m
S P01036 121 1-20 Removed, 2 disulfide
bonds
S1 P01036 121 1-20 Removed, 2 disulfide
bonds, phosphorylation
S2 P01036 121 1-20 Removed, 2 disulfide
bonds, 2
phosphorylation
SA P09228 121 1-20 Removed, 2 disulfide
bonds
SN P01037 121 1-20 Removed, 2 disulfide
bonds
SN (SNP) P01037 121 1-20 Removed, 2 disulfide
bonds, rs2070856
(P31L)
C P01034 120 1-26 Removed, 2 disulfide
bonds
D (SNP) P28325 114 1-28 Removed, 2 disulfide
bonds, rs1799841
(C46R)
D (SNP) P28325 118 1-24 Removed, 2 disulfide
bonds, rs1799841
(C46R)
aRoot mean square of error on product ion assignments (within 10 pp
bValues taken from reference [26].
cDetected by FT-ICR-MS only.on cystatins in the literature. Average mass is used for
traditional “intact mass tags” [27] whereas monoisotopic
mass is used for high-resolution intact mass tags.
Protein Identification
Attempts to identify cystatins in ProSight PC’s “abso-
lute mass” mode typically fail when full genomic trans-
lations are used in the database. This is because N-
terminal residues need to be removed before b-ions are
matched and two disulfides oxidized before y-ions are
matched. Fortunately, the N-terminal half of the cyst-
atins frequently yields good b- and y-ion series resulting
in sequence tags that can be used to identify them using
this functionality within ProSight PC. Custom anno-
tated databases are then created with corrected N-
termini, post-translational modifications and protein
sequence polymorphisms.
Cystatin S, S1, and S2
The cystatins have an N-terminal signal peptide that is
cleaved during maturation of the protein. In the case of
cystatin S (P01036), the first 20 amino acids are cleaved
to give a 121 amino acid protein with a calculated
monoisotopic mass of 14,179.8005 Da (Table 1). The
experimentally determined monoisotopic mass of
14,175.8569 Da for the HPLC peak eluting at 48 min
ured
age
(Da)
Calculated
monoisotopic
mass after
modification
(Da)
Experimental
monoisotopic
mass (FTMS)
(Da)
Delta
(Da)
Delta
(ppm)
RMSa
(ppm)
86 14175.8005 14175.8569 0.0564 3.98 3.69
66 14255.7668 14255.8567 0.0899 6.30 4.26
46 14335.7335 14335.8110 0.0775 5.40 4.75
47 14337.0014 14336.9856 0.0158 1.10 6.55
13 14303.2228 14303.1553 0.0675 4.72 5.00
28 14319.1187 14319.171b 0.0523 3.65b 7.07b
45 13334.5969 13334.5829 0.0140 1.05 3.90
65 13154.4776 13154.4675 0.0101 0.77 2.47
c 13596.7064 13596.7015 0.0049 0.36 0.35
erance).eas
aver
ass
141
142
143
143
143
143
133
131
ND
m tol
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sistent with a mass loss associated with the formation of
a pair of disulfide bonds (4.0313 Da). Oxidation of the
four Cys residues in cystatin S to form two disulfide
bonds between Cys94-Cys104 and Cys118-Cys138 in
conservation with all the salivary cystatins brings coin-
cidence of measured and calculated masses to better
than 4 ppm (  0.0564 Da, 3.98 ppm). Analysis of the
CAD dataset for the disulfide-oxidized N-truncated
protein using ProSight PC 2.0 (tolerance of 10 ppm;
deltamass mode off) yielded 10 matching b-ions. After
manual modification of the four Cys residues to account
for the formation of two disulfide bonds (1.0078 each
residue) the software analysis yielded 11 b- and 27
y-product ions, agreement of calculated and measured
mass within 10 ppm and a P-Score of 1.71E-57 (Figure 2,
Table 1).
Cystatin S is monophosphorylated at Ser23
(position 3 of the mature form) to produce a post-
translationally modified form, cystatin S1 [28–30].
The experimentally determined monoisotopic mass
of 14,255.8567 Da for the HPLC peak eluting at 48 min
is within 10 ppm of the calculated mass of the mature
cystatin S1 protein, including two disulfide bonds
Cystatin S
Cystatin S1
Cystatin S2
1183.20
11841182
m/z
1019.85
10211019 m/z
1305.00
13071304
m/z
Figure 2. Top-down mass spectrometry of c
analyzed by static nanospray on a 7 T LTQ-FT
yielded complex tandem mass spectra that we
Methods section). The precursor ion isolation use
the b- and y-product ion assignments observed at
shown superimposed on the sequence to the righ
from the precursor sequence and each Cys residu
pair of disulfide bonds of the native protein. Fo
and y-ions giving a P-Score of 1.71E-57. For cyst
added at position 3 of the mature protein with 31
For cystatin S2, a second phosphorylation was a
product ions matched and a P-Score of 8.06E-32.and a single phosphorylation (14,255.7668 Da;  
0.0899 Da, 6.30 ppm). An absolute mass search with
ProSight PC 2.0 yielded only one artifactual matching
y-fragment ion until oxidation of the four cysteines
(two disulfide bonds; 4.03130036 Da) and phos-
phorylation of Ser23 (79.9663 Da) were introduced
yielding 14 b- and 28 y-product ions matched, and a
P-Score of 4.75E-42 (Figure 2, Table 1). The detection
of the y119 product ion provides definitive evidence
that the singly phosphorylated form is modified at
Ser23, although this may not be exclusive; some
modification at Ser21 or Ser22 cannot be ruled out
based on the observed coverage.
Cystatin S is also known to be diphosphorylated at
Ser21 and at Ser23 [28] to produce another post-
translationally modified form, cystatin S2. The experi-
mentally determined monoisotopic mass of 14,335.8110
Da for the HPLC peak eluting at 48 min is in good
agreement with the calculated mass for the mature
protein, including two disulfide bonds and two phos-
phorylations (14,335.7335 Da;   0.0775 Da, 5.40 ppm).
The CAD product ion peaklist could only be matched to
the primary structure of cystatin S after manual modi-
fication of the four cysteine residues (2 disulfides;
ns S, S1, and S2. Appropriate fractions were
. CAD experiments on isolated precursor ions
terpreted using ProSight PC software (see the
each experiment is shown on the left (m/z) while
pm tolerance (deltamass feature deactivated) are
20 amino acid signal peptide has been removed
s been oxidized (1.0078 Da) to reflect the intact
tatin S 41% of product ions were matched to b-
1, a single phosphorylation (79.9663 Da) was
product ions matched and a P-Score of 4.75E-42.
at position 1 of the mature protein with 26% ofystati
Ultra
re in
d for
10 p
t. A
e ha
r cys
atin S
% of
dded
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(159.9326 Da), sequence coverage increased signifi-
cantly with 5 b- and 19 y-fragment ions matched to the
CAD dataset and a P-Score of 8.06E-32 (Figure 2, Table
1). Some modification of Ser22 cannot be ruled out
based on the observed coverage.
All three experiments on the cystatin S family
yielded b- and y-fragments from the region between
Cys104 and Cys118 supporting disulfide crosslinking of
Cys94 to Cys104 and Cys118 to Cys138 rather than
some other arrangement. Based upon this observation
no further analysis of disulfide bonding was deemed
necessary. Annotation of human salivary cystatin disul-
fide crosslinking has generally been achieved by simi-
larity to the original work on egg-white cystatin and
human cystatin C [31]. The minor adduct seen on each
ion isolation has a deltamass of 12 Da and is as yet
unidentified.
Identification and Characterization of Cystatin SA,
SN, and C
Cystatins SA and SN have a signal peptide consisting of
the first twenty amino acids while that of cystatin C
consists of the first 26 amino acids. The mature forms of
Cystatin SA
Cystatin SN
Cystatin C
1025.65
1025                  1027 m/z
895.46
895             896 m/z
954.05
953                  955 m/z
Figure 3. Top-down mass spectrometry of cy
analyzed as in Figure 2. For cystatin SA and SN
for cystatin C a 26 amino acid peptide was remov
Each Cys residue has been oxidized (1.0078 D
native protein. For cystatin SA, 34% of product
cystatin SN, 30% of product ions were matched
product ions were matched giving a P-Score of 1.25Ecystatin SA and SN contain 121 amino acids while
cystatin C has 120 amino acids (Table 1). Cystatins SA,
SN, and C all contain two disulfide bonds in homology
with the family (see Figure 5). Cystatins SA and SN
have these bonds between Cys94-Cys104 and Cys118-
Cys138, while cystatin C has these bonds between Cys99-
Cys109 and Cys123-Cys143. The mature form of cystatin
SA in the peak eluting at 48 min has an experimentally
determined monoisotopic mass of 14,336.9856 Da, in
agreement with the calculated monoisotopic mass of
14,337.0014 Da, including the two disulfide bonds ( 
0.0158, 1.10 ppm). A top-down CAD experiment con-
firmed the identity of cystatin SA with 6 b- and 27
y-product ions as well as the precursor matched within
10 ppm giving a P-Score of 2.81E-46 (Figure 3; Table 1).
The mature form of cystatin SN in the peak eluting at 42
min has an experimentally determined monoisotopic
mass of 14,303.1553 Da, in agreement with the calcu-
lated monoisotopic mass of 14,303.2228 Da, including
two disulfide bonds (  0.0675, 4.72 ppm). A top-
down CAD experiment confirmed the identity of
cystatin SN with 8 b- and 13 y-product ions as well as
the precursor matched within 10 ppm giving a P-
Score of 4.30E-29 (Figure 3; Table 1). The mature form
of cystatin C in the peak eluting at 45 min has an
s SA, SN, and C. Appropriate fractions were
amino acid signal peptide was removed while
onserving the N-terminus of the mature protein.
reflect the intact pair of disulfide bonds of the
were matched giving a P-Score of 2.8E-46. For
ng a P-Score of 4.3E-29. For cystatin C, 22% ofstatin
, a 20
ed, c
a) to
ions
givi-34.
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1237.77
1504.94
1485.12
996.18
1273.13
953.49
1294.47
974.83
1527.55
1047.62
m/z
m/z
400 2000
1504.93
1485.12
1527.55
1254.45
m/z400 2000
1197.60
m/z
Cystatin D (29-142)
y64
y63
y65
y63
y65
y64
b52b51
b53
926.31
b50
m/z
941.32
b50922.47
b49
901.13
b48
m/z
y64
y63
y65
y64
(a)
(b)
Figure 4. Top-down mass spectrometry of two isoforms of cystatin D. (a) A protein of average mass
13,605 Da that was not detected by LC-MS was analyzed by top-down CAD of the 13 precursor ion
(inset top right) giving the product ion spectrum shown. The precursor and product ion masses were
accounted for by removing 24 amino-acids from the N-terminus of the human cystatin D sequence,
oxidizing the 4 Cys residues to reflect two disulfide bonds and making the C46R polymorphism arising
from a known SNP (Table 1); 31% of product ions werematched giving a P-Score of 3.44E-18. (b) A protein
of average mass 13,165 Da that was detected by LC-MS was analyzed by top-down CAD of the 11
precursor ion (inset top right) giving the product ion spectrum shown. The precursor and product ion
masses were accounted for by removing 28 amino-acids from the N-terminus of the human cystatin D
sequence, oxidizing the 4 Cys residues to reflect two disulfide bonds andmaking the C46R polymorphism
arising from a known SNP (Table 1); 51% of product ions were matched giving a P-Score of 2.0E-22. A
small section of the product ion spectrum was expanded to show unique b-ions [top left in (a) and (b)].
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13,334.5829 Da, in agreement with the calculated
monoisotopic mass of 13,334.5969 Da, including two
disulfide bonds (  0.0140 Da, 1.05 ppm). A top-
down CAD experiment confirmed the identity of
cystatin C with 9 b- and 18 y-product ions as well as
the precursor matched within 10 ppm giving a P-
Score of 1.25E-34 (Figure 3; Table 1).
Truncation of Cystatin D with a Protein Sequence
Polymorphism
As was the case for the other cystatins, cystatin D has a
signal peptide reported to consist of the first twenty
amino acids that is cleaved to form the mature 122
amino acid protein, and like the other cystatins, cystatin
D contains two disulfide bonds, between Cys95-Cys105
and Cys119-Cys139 by homology to the family. In our
experiments, two previously undescribed forms of cys-
tatin D were identified both with a single nucleotide
polymorphism (SNP; rs1799841) that resulted in the
protein sequence polymorphism C46R and, unlike any
of the other cystatins, both were differentially truncated
at their N-termini resulting in two distinct mature
proteins, with residues 25-142 and 29-142 (Table 1).
Top-down CAD experiments confirmed the primary
structure of the two novel isoforms of cystatin D (Figure
4). The larger form had an experimental monoisotopic
Figure 5. Sequence alignment of the abundant
alignment [36].
Table 2. Relative abundance of human salivary cystatins
Cystatin Swiss-Prot accession no. Average mass
S P01036 14186
S1 P01036 14266
S2 P01036 14346
SA P09228 14347
SN P01037 14313
SN  SNP P01037 rs2070856 14328
C P01034 13345
D (SNP) 29-142 P28325 rs1799841 13165
D (SNP) 25-142 P28325 rs1799841 (13605)b
a, , ,   relative abundance;   not detected.
bDetected by FT-ICR-MS only.mass of 13,596.7015 Da in good agreement with the
calculated monoisotopic mass of 13,596.7064 Da ( 
0.0049 Da, 0.36 ppm) with the CAD experiment yielding
6 b- and 7 y-fragment ions matched for a P-Score of
3.44E-18 (Figure 4a). The smaller form had an experi-
mental monoisotopic mass of 13,154.4675 Da in good
agreement with the calculated monoisotopic mass of
13,154.4776 Da (  0.0101 Da, 0.77 ppm) with the CAD
experiment yielding 7 b- and 6 y-fragment ions matched
for a P-Score of 2.00E-22 (Figure 4b). No evidence was
found for cystatin D (with C46R) cleaved at the reported
signal peptide site 21–142 with calculated monoisotopic
mass of 13,845.7368 Da. Common y-ions that dominate
the product ion spectrum can be seen in both experi-
ments while unique b-ions distinguishing the two iso-
forms are present, some of which are shown expanded
in Figure 4.
Origin of Cystatins
The measurements described were obtained on samples
from either whole saliva or a mixture of submandibu-
lar/sublingual (SMSL) ductal secretions. The chromato-
gram for parotid saliva (Figure 1) shows only small
inflections in the region where the cystatins are known
to elute. Examination of the low-resolution ESI-MS data
collected during LC-MS showed no detectable intact
mass tags for any of the cystatin family (Table 2). While
an salivary cystatins. ClustalW was used for the
Whole salivaa SM/SLa Parotida Elution time (min)
   55
   55
   55
   60
   48
   48
   52
   50
 ()b  50hum(Da)
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proteins in SM versus SL salivary secretions [32], the
cystatin profiles looked similar when analyzed by LC-
MS (data not shown). It is noted that the static
nanospray FT-ICR-MS experiments are more sensitive
than LC-MS and that the larger form of cystatin D
with calculated average mass of 13,605 Da was only
detected by FT-ICR-MS. An alignment of the human
cystatin family is shown in Figure 5.
The experimental measurements described define
high-resolution intact mass tags (IMTs) for eight human
salivary cystatins, supplementing our previous top-
down study that revealed the P31L polymorphism of
cystatin SN [26]. Extensive mass spectrometry studies
of human saliva proteins have established a database of
knowledge with respect to the primary structure and
post-translational modifications of the intact salivary
proteome [25]. Most of this previous work was per-
formed using low-resolution electrospray-ionization in-
struments that generally provide a convenient means to
follow different abundant salivary proteins. High-
resolution top-down MS provides a significant advan-
tage however, in cases where lower resolution instru-
ments might yield ambiguous results. For example, the
top-down MS analysis of the P31L isoform of cystatin
SN allowed us to distinguish this isoform from a
previously described oxidized form of this protein [9,
25]. Both precursor and product ion assignments were
significantly better using a  of CH4 (calculated mass 
16.0313 Da) rather than O (15.9949 Da) and product ion
assignments from CAD and ECD experiments localized
the modification at position 11 of the mature protein,
illustrating the power of the top-down, high-resolution
MS approach. Likely, other researchers will more fre-
quently use high-resolution approaches as MS instru-
mentation becomes widely available and, for example,
it is noted that a recent review reports the presence of
acrylonitrile adducts (53 Da) on the P-B peptide based
upon analysis of human saliva using an Orbitrap ana-
lyzer [33]. Once IMTs are defined, they can be used to
monitor changes in abundance in different samples. For
example, Messana and coworkers used IMTs to track
changes in saliva proteins across subjects of different
ages, and to compare normal subjects with autism
patients [34, 35].
Previously, human cystatin D was reported to have
an intact mass of 13,848 Da, supporting a 20 amino acid
signal peptide and conservation of the N-terminus with
other cystatins [9], while a subsequent study from the
same group failed to detect it in a range of samples
including whole saliva as well as ductal secretions from
parotid and SMSL [25]. In the present study, two
truncated isoforms of cystatin D were characterized in
molecular detail, with removal of either 24 or 28 amino-
acids from the N-terminus, as well as the known C46R
polymorphism. Since protease inhibitors were used and
other cystatins had N-termini in agreement with the
literature it is concluded that cystatin D is unusually
sensitive to N-terminal proteolysis resulting in thetruncated forms. A previous study reported detection of
proteins in the mass range 12,582–13,904 that were
hypothetically matched to N-terminally trimmed cyst-
atins including D [9]. The masses reported here agree
with those previously reported for cystatins S, S1, S2,
SA, SN, and C [9]. Recently, Toyoshima’s group re-
ported that a truncated form of cystatin SA with three
extra amino acids removed from the N-terminus
showed significant differential expression in patients
with oral squamous cell carcinoma [18].
Bottom-up strategies have been used to extensively
map the human salivary proteome [20] and detected all
of the cystatins described here as well as cystatin B that
has yet to be characterized in its intact state. Cystatin B
is a smaller sized protein and lacks the paired disulfide
motif of the cystatins described here. While none of the
cystatins was detected by top-down MS analysis of
parotid saliva in this study, it is noted that all members
were detected in the bottom-up study and also in the
intact protein analysis of parotid saliva [25].
Conclusions
The top-down MS analyses described herein were ade-
quate to confidently assign an intact mass tag (IMT) to
a gene and to fully confirm the primary structure in the
context of a genomic translation. Novel or labile post-
translational modifications in regions of the protein
with poor bond cleavage could require more detailed
experiments, including reduction of the disulfides and
additional dissociation modes such as ECD, as was
used in the description of the P31L isoform of cystatin
SN [26]. The hybrid linear ion-trap FT-ICR mass spec-
trometer used for the top-down MS experiments
achieved mass accuracy on precursor and product ions
that was typically better than 5 ppm. This and similar
high-resolution instruments such as the Fourier-
transform Orbitrap represent powerful tools for top-
down proteomics and biomarker discovery. Moreover,
we envision that there will be a substantial future for
monitoring intact saliva proteins for biomarkers and
biosignatures of human disease.
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